Month: January 2024

The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final patient is enrolled.   BOCA RATON, Florida, Jan. 30, 2024 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB)  (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, received correspondence from the FDA confirming that the full clinical hold on the Company’s AD clinical trial program has been lifted. The Phase II trial is on track to enroll the last patient mid-2024. Top line data is expected approximately six months after the last patient is enrolled. “We are...

FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the publication of positive data from a study of the second generation Pure-Vu System in a manuscript titled, “An intraprocedural bowel cleansing system for difficult-to-prepare patients—A multicenter prospective feasibility study,” in the peer-reviewed journal, United European Gastroenterology (UGE). The Company’s Pure-Vu System is an FDA-approved and CE-certified bowel cleansing system (BCS) intended to increase visualization in inadequately prepared colons by offering intraprocedural cleansing. “We are excited to see the positive results from this European study published in the UGE Journal, further...

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) — Mizuho Americas today announced its strategic investment in DirectBooks®, the leading primary markets communications platform. Through this investment, Mizuho will join the board of directors and work directly with other top-tier investment banks to enhance capital markets globally. “DirectBooks has emerged as an important provider of innovative solutions for the capital markets,” said Jerry Rizzieri, President and CEO, Mizuho Securities USA. “We look forward to playing a larger role in their continued success.” DirectBooks is a fintech bank consortium founded with the goal of optimizing capital markets through streamlined communication resulting from structured deal data, documentation, and information exchange. Mizuho Americas joined the DirectBooks platform as the first non-consortium...

MISSISSAUGA, Ontario, Jan. 30, 2024 (GLOBE NEWSWIRE) —  goeasy Ltd. (TSX: GSY), (“goeasy” or the “Company”), one of Canada’s leading non-prime consumer lenders, will hold a conference call with shareholders, analysts, and portfolio managers on Wednesday, February 14, 2024. A media release including goeasy Q4 2023 results will be issued after the market closes on Tuesday, February 13, 2024. Date: Wednesday, February 14, 2024 Time: 11:00 am ET Dial-in: Use the link https://register.vevent.com/register/BI4bff80379a124f35890a33569bbd294c to pre-register for the conference call and obtain your dial-in number and unique PIN. A recorded version will be available under the same link immediately following the conclusion of the conference call. Webcast: https://edge.media-server.com/mmc/p/agqex44d Media are invited to listen to the...

Figure 1.Geological map illustrating the drillholes at the Cumavici Ridge locality. AgEq values are labelled for selected 2022 and 2023 drill intercepts (See Company’s new releases dated 13 November 2023, 27 February 2023, 17 January 2024). Current drilling efforts confirm mineralization over 82 m NW/SE strike length. (WGS84/UTM Zone 34N)Figure 2.Drillhole section through step out drill fence located 42 m SE of the 2022 discovery holes at Cumavici Ridge. Assay intervals reported for CMV23001.News Release Video: Terra Balcanica produced a technical webinar to explain the drill results VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) — Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1) is pleased to announce the final geochemical assay results from the Phase II drill campaign...

DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will deliver a presentation at the 7th DDR Inhibitors Summit, to take place January 30 to February 1, 2024 in Boston, MA. “We are excited to have the opportunity to present at the DDR Inhibitors Summit,” said Dr. Oren Gilad. “DDR has been identified as an important pathway for treating cancer, and there is considerable ongoing progress in the development of potential new therapeutics. Aprea is positioned at the forefront of this wave of innovation, and we look forward to providing an update to the oncology community at this year’s summit.”Presentation DetailsTitle:     Prioritizing...